Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease

Opinion
Video

This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, contextualize data from large studies regarding the utilization of neurofilament light chain.

In this segment, Ahmed Obeidat, MD, PhD, provides a concise summary of recent studies that investigated the correlation between neurofilament light chain (NFL) levels and long-term disability in multiple sclerosis (MS) patients. He mentions that these studies indicate a potential role for NFL in predicting disability accumulation over several years, challenging the previous assumption that NFL primarily correlates with inflammation rather than the neurodegenerative process.

Ahmed Obeidat, MD, PhD, also highlights that the predictive power of NFL seems more robust in the relapsing MS population compared to those with progressive MS. He emphasizes the accumulating evidence from various cohorts and countries supporting the potential use of NFL, along with other biomarkers, in predicting long-term outcomes on a population level.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.

This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Related Videos
Jaime Imitol, MD
Prashanth Rajarajan, MD, PhD
Riley Bove, MD
Bruce Bebo, PhD
© 2024 MJH Life Sciences

All rights reserved.